Home Liver Diseases The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial

The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial

Credits to the Source Link Daniel
The efficacy of flaxseed and hesperidin on non-alcoholic fatty liver disease: an open-labeled randomized controlled trial
  • 1.

    Liver EAFTSOT, Diabetes EAftSo. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65–90.


    Google Scholar
     

  • 2.

    Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–85.

    CAS 
    PubMed 

    Google Scholar
     

  • 3.

    Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–53.

    PubMed 

    Google Scholar
     

  • 4.

    Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–96.

    CAS 
    PubMed 

    Google Scholar
     

  • 5.

    Watanabe M, Tozzi R, Risi R, Tuccinardi D, Mariani S, Basciani S, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature. Obes Rev. 2020;21:e13024.

  • 6.

    Laursen TL, Hagemann CA, Wei C, Kazankov K, Thomsen KL, Knop FK, et al. Bariatric surgery in patients with non-alcoholic fatty liver disease-from pathophysiology to clinical effects. World J Hepatol. 2019;11:138.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 7.

    Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway. Br J Pharmacol. 2018;175:3379–93.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 8.

    Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349:24–8.


    Google Scholar
     

  • 9.

    Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–66.

    PubMed 

    Google Scholar
     

  • 10.

    Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The role of medications for the management of patients with NAFLD. Clin Liver Dis. 2014;18:73–89.

    PubMed 

    Google Scholar
     

  • 11.

    Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr. 2014;33:186–90.

    PubMed 

    Google Scholar
     

  • 12.

    Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS ONE. 2014;9:e111808.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 13.

    Greenway F. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes. 2015;39:1188.

    CAS 

    Google Scholar
     

  • 14.

    Pugh CJ, Sprung V, Jones H, Richardson P, Shojaee-Moradie F, Umpleby AM, et al. Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease. Int J Obes. 2016;40:1927.

    CAS 

    Google Scholar
     

  • 15.

    Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol. 2017;9:503–9.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 16.

    Noori M, Jafari B, Hekmatdoost A. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. J Sci Food Agric. 2017;97:2327–32.

    CAS 
    PubMed 

    Google Scholar
     

  • 17.

    Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Hepat Mon. 2016;16:e34897.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 18.

    Emamat H, Foroughi F, Eini-Zinab H, Taghizadeh M, Rismanchi M, Hekmatdoost A. The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. J Diabetes Metab Disord. 2015;15:25.

    PubMed 

    Google Scholar
     

  • 19.

    Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016;67:461–9.

    CAS 
    PubMed 

    Google Scholar
     

  • 20.

    Morris DH. Flax: a health and nutrition primer. Flax Council of Canada; Winnipeg, MB, Canada, 2007.

  • 21.

    Daun JK, Barthet VJ, Chornick TL, Duguid S. Structure, composition, and variety development of flaxseed. Flaxseed in human nutrition: AOCS Publishing; Champaign, Illinois, 2003. p. 6–45.

  • 22.

    Hassanali Z, Ametaj B, Field C, Proctor S, Vine D. Dietary supplementation of n‐3 PUFA reduces weight gain and improves postprandial lipaemia and the associated inflammatory response in the obese JCR: LA‐cp rat. Diabetes Obes Metab. 2010;12:139–47.

    CAS 
    PubMed 

    Google Scholar
     

  • 23.

    Tai CC, Ding ST. N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention. J Nutr Biochem. 2010;21:357–63.

    CAS 
    PubMed 

    Google Scholar
     

  • 24.

    Yari Z, Rahimlou M, Poustchi H, Hekmatdoost A. Flaxseed supplementation in metabolic syndrome management: a pilot randomized, open‐labeled, controlled study. Phytother Res. 2016;30:1339–44.

    CAS 
    PubMed 

    Google Scholar
     

  • 25.

    Rhee Y, Brunt A. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J. 2011;10:44.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 26.

    Edel AL, Rodriguez-Leyva D, Maddaford TG, Caligiuri SP, Austria JA, Weighell W, et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol-lowering medications alone in patients with peripheral artery disease–4. J Nutr. 2015;145:749–57.

    CAS 
    PubMed 

    Google Scholar
     

  • 27.

    Mohammadi‐Sartang M, Mazloom Z, Raeisi‐Dehkordi H, Barati‐Boldaji R, Bellissimo N, Totosy, et al. The effect of flaxseed supplementation on body weight and body composition: a systematic review and meta‐analysis of 45 randomized placebo‐controlled trials. Obes Rev. 2017;18:1096–107.

    PubMed 

    Google Scholar
     

  • 28.

    Yari Z, Rahimlou M, Hekmatdoost A. Flaxseed supplementation improves anthropometric measurements, metabolic, and inflammatory biomarkers in overweight and obese adults. Int J Vitamin Nutr Res. 2019;1–8.

  • 29.

    Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727–47.

    CAS 
    PubMed 

    Google Scholar
     

  • 30.

    Rizza S, Muniyappa R, Iantorno M, Kim J-A, Chen H, Pullikotil P, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96:E782–E92.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 31.

    Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and anti‐inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res. 2015;29:323–31.

    CAS 
    PubMed 

    Google Scholar
     

  • 32.

    De Ledinghen V, Vergniol J. Transient elastography (fibroscan). Gastroenterol Clin Biol. 2008;32:58–67.

    PubMed 

    Google Scholar
     

  • 33.

    Initiative NOE, Heart N, Lung, Institute B, Obesity NAAftSo, Identification EPot, et al. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults: The Institute; Bethesda, Maryland, 2000.

  • 34.

    Kelishadi R, Rabiei K, Khosravi A, Famouri F, Sadeghi M, Rouhafza H, et al. Assessment of physical activity of adolescents in Isfahan. J Shahrekord Univ Med Sci. 2001;3:55–66.

  • 35.

    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

    CAS 
    PubMed 

    Google Scholar
     

  • 36.

    Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6:299–304.

    PubMed 

    Google Scholar
     

  • 37.

    Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 38.

    Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 39.

    Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Domínguez N, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:160–3.

    PubMed 

    Google Scholar
     

  • 40.

    Torkan M, Entezari MH, Siavash M. Effect of flaxseed on blood lipid level in hyperlipidemic patients. Rev Recent Clin Trials. 2015;10:61–7.

    CAS 
    PubMed 

    Google Scholar
     

  • 41.

    Patade A, Devareddy L, Lucas EA, Korlagunta K, Daggy BP, Arjmandi BH. Flaxseed reduces total and LDL cholesterol concentrations in Native American postmenopausal women. J Women’s Health. 2002;17:355–66. 2008


    Google Scholar
     

  • 42.

    Xu J, Yang W, Deng Q, Huang Q, Huang F. Flaxseed oil and α-lipoic acid combination reduces atherosclerosis risk factors in rats fed a high-fat diet. Lipids Health Dis. 2012;11:148.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • 43.

    Di Y, Jones J, Mansell K, Whiting S, Fowler S, Thorpe L, et al. Influence of flaxseed lignan supplementation to older adults on biochemical and functional outcome measures of inflammation. J Am Coll Nutr. 2017;36:646–53.

    CAS 
    PubMed 

    Google Scholar
     

  • 44.

    Felmlee MA, Woo G, Simko E, Krol ES, Muir AD, Alcorn J. Effects of the flaxseed lignans secoisolariciresinol diglucoside and its aglycone on serum and hepatic lipids in hyperlipidaemic rats. Br J Nutr. 2009;102:361–9.

    CAS 
    PubMed 

    Google Scholar
     

  • 45.

    Salden BN, Troost FJ, de Groot E, Stevens YR, Garcés-Rimón M, Possemiers S, et al. Randomized clinical trial on the efficacy of hesperidin 2S on validated cardiovascular biomarkers in healthy overweight individuals. Am J Clin Nutr. 2016;104:1523–33.

    CAS 
    PubMed 

    Google Scholar
     

  • 46.

    Mohammadi M, Ramezani-Jolfaie N, Lorzadeh E, Khoshbakht Y, Salehi-Abargouei A. Hesperidin, a major flavonoid in orange juice, might not affect lipid profile and blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. Phytother Res. 2019;33:534–45.

  • 47.

    Jung UJ, Lee M-K, Park YB, Kang MA, Choi M-S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J Biochem cell Biol. 2006;38:1134–45.

    CAS 
    PubMed 

    Google Scholar
     

  • 48.

    Lawrenz J, Herndon B, Kamal A, Mehrer A, Dim DC, Baidoo C, et al. Dietary flaxseed oil protects against bleomycin-induced pulmonary fibrosis in rats. Pulmonary medicine. 2012;2012:457031.

  • 49.

    Xu J, Gao H, Song L, Yang W, Chen C, Deng Q, et al. Flaxseed oil and alpha-lipoic acid combination ameliorates hepatic oxidative stress and lipid accumulation in comparison to lard. Lipids Health Dis. 2013;12:58.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 50.

    Dentin R, Benhamed F, Pégorier J-P, Foufelle F, Viollet B, Vaulont S, et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. The. J Clin Investig. 2005;115:2843–54.

    CAS 
    PubMed 

    Google Scholar
     

  • 51.

    Marx N, Duez H, Fruchart J-C, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168–78.

    CAS 
    PubMed 

    Google Scholar
     

  • 52.

    Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 2008;19:242.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 53.

    Hutchins AM, Brown BD, Cunnane SC, Domitrovich SG, Adams ER, Bobowiec CE. Daily flaxseed consumption improves glycemic control in obese men and women with pre-diabetes: a randomized study. Nutr Res. 2013;33:367–75.

    CAS 
    PubMed 

    Google Scholar
     

  • 54.

    Ghanim H, Sia CL, Upadhyay M, Korzeniewski K, Viswanathan P, Abuaysheh S, et al. Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. Am J Clin Nutr. 2010;91:940–9.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • 55.

    Hallund J, Tetens I, Bügel S, Tholstrup T, Bruun JM. The effect of a lignan complex isolated from flaxseed on inflammation markers in healthy postmenopausal women. Nutr Metab Cardiovas Dis. 2008;18:497–502.

    CAS 

    Google Scholar
     

  • 56.

    Nasri K, Hantoushzadeh S, Aghadavod E, Taghizadeh M, Asemi Z. The effects of omega-3 fatty acids supplementation on gene expression involved in the insulin and lipid signaling pathway in patients with polycystic ovary syndrome. Horm Metab Res. 2017;49:446–51.

    CAS 
    PubMed 

    Google Scholar
     

  • 57.

    Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-α expression by preventing NF-κB activation. J Am Coll Nutr. 2004;23:71–8.

    CAS 
    PubMed 

    Google Scholar
     

  • 58.

    Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: an acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon. 2011;11:157.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: